These are the stocks posting the largest moves before the bell.Market Insiderread more
Facebook will also create a new subsidiary, Calibra, to build a digital wallet for people to store and exchange the currency using apps.Technologyread more
President Donald Trump went after European Central Bank President Mario Draghi on Tuesday for opening the door for more monetary stimulus in Europe, which would weaken the...Marketsread more
"I do think there will be a resolution before the end of the year" in the U.S.-China trade war, says private equity billionaire David Rubenstein.Economyread more
Experts expect Facebook's cryptocurrency venture to alleviate some security issues, while introducing new ones.Cybersecurityread more
European Central Bank President Mario Draghi defended the tools that the organization has available.Europe Newsread more
The chipmaker crush could persist and investors should be selective, but Nvidia looks like a clear buy, one market watcher says.Trading Nationread more
Trump's disruptive trade confrontations have sent shockwaves through the business world, while, insiders say, companies may wonder whether associating with the president could...Politicsread more
Facebook shares rose in premarket trading after the tech giant unveiled its part in a new digital currency.Marketsread more
According to China's top economic planning body, some local companies are cutting back on their efforts to hire new university graduates.China Economyread more
Americans for Prosperity, the political arm of the vast group co-founded by libertarian billionaire Charles Koch, announces it will back the one-term Republican to defend a...Politicsread more
business@ (Adds details from company statement on reason for retaining Amitiza)
May 28 (Reuters) - Mallinckrodt Plc said on Tuesday it would spin off its generics unit and keep constipation medicine Amitiza as part of its branded drugs business, to be renamed Sonorant Therapeutics Plc.
The company had said in December it was open to a sale of the generics business or would spin it off in second half of 2019. It had said Amitiza would be part of the spun-off unit.
On Tuesday, the company said it believed the new generics company, to be called Mallinckrodt Inc, would emerge with less debt than previously anticipated without the Amitiza drug.
The specialty generics unit's sales in 2018 were $722.6 million, excluding Amitiza. (Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)